HAL Allergy Prick Test Hausstaubmilbe Dermatophagoides Pteronyssinus
Sponsors
HAL Allergy B.V., Inmunotek S.L.
Conditions
Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with or without AsthmaGrass pollen induced allergic rhinitis or rhinoconjunctivitisModerate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergybirch pollen-induced allergic rhinitis
birch pollen-induced allergic rhinoconjunctivitis
Phase 2
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated allergoid Dactylis glomerata/Phleum pratense administered subcutaneously to patients with grass pollen-induced allergic rhinitis or rhinoconjunctivitis.
Not yet recruitingCTIS2025-524580-21-00
Target: 450Updated: 2026-05-29
A Prospective, Randomized, Open-label, Multicentre Study to Compare the Safety of PURETHAL Mites Mixture 50,000 AUeq/mL Rush Up-Dosing Regimen with the Conventional Up-Dosing Regimen in Adult Participants with Allergic House Dust Mite Rhinitis/Rhinoconjunctivitis with or without Asthma
Not yet recruitingCTIS2026-526908-72-00
Target: 15Updated: 2026-10-14
Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Active, not recruitingCTIS2023-504942-75-01
Start: 2024-08-22Target: 582Updated: 2025-12-16
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2024-515717-17-00
Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07